ClinicalTrials.gov
ClinicalTrials.gov Menu

Blood Compatibility Characteristics of Baxter Xenium+, Fresenius FX and Gambro Polyflux Dialyzers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01273870
Recruitment Status : Completed
First Posted : January 11, 2011
Last Update Posted : February 2, 2011
Sponsor:
Information provided by:
Praxisverbund Dialyse und Apherese

Brief Summary:
The aim of the dialyzer evaluation is to compare performance characteristics and haemocompatibility of the Baxter Xenium+ (Polynephron), Fresenius FX and Gambro Polyflux dialyzers

Condition or disease
End Stage Renal Failure on Dialysis

Detailed Description:

The Xenium+ is a new high flux dialyzer made from Polynephron membrane designed and manufactured by the Nipro Company in Japan. This dialyzer has been subjected to in-vitro testing, and all legally required biological safety tests have been conducted and CE-mark was granted in June 2010. Xenium+ has the same Polynephron membrane as the Xenium family of dialyzers which has been available commercially globally for approximately three years. Clinical evaluations have been completed with the Polynephron membrane within the last three years. The improvement in the Xenium+ line is that the casing is now made from polypropylene.

The aim of the dialyzer evaluation is to compare performance characteristics and hemocompatibility of the Xenium+ (Polynephron), Fresenius FX and Gambro Polyflux dialyzers.


Study Type : Observational
Actual Enrollment : 8 participants
Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Post Marketing Surveillance Investigating Blood Compatibility Characteristics of Baxter Xenium+, Fresenius FX and Gambro Polyflux Dialyzers
Study Start Date : December 2010
Actual Primary Completion Date : January 2011
Actual Study Completion Date : February 2011



Primary Outcome Measures :
  1. Clearance for urea, phosphate, beta-2-microglobulin blood cell drop, complement factor C5a, TAT [ Time Frame: January 2011 ]

Secondary Outcome Measures :
  1. General survey of the dialysis treatments [ Time Frame: January 2011 ]
    Registration of adverse effects of the dialysis treatments



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
8 patients will undergo 1 treatment each with the 4 high-flux dialyzer types using a bloodflow of 300 ml/min, dialysate flow 500 ml/min and the dialysis machine Fresenius 5008
Criteria

Inclusion Criteria:

  • ESRD patients 18 years or older
  • Stable on hemodialysis for more than 3 months
  • An average haematocrit value of 30 % or higher in the last three 3 months
  • Stable vascular access of either a fistula or graft
  • Stable anticoagulation and regimen
  • Stable erythropoiesis-stimulating agent (ESA) regimen for the last three 3 months
  • No active infection
  • Able to sign informed consent and able to participate in the study
  • Medically stable

Exclusion Criteria:

  • Participation in another study which may interfere with the planned study
  • Active infection
  • Medical conditions which may interfere with the study (cardiac, liver disease, hepatitis)
  • Female(s) who are pregnant or planning to be pregnant
  • Problem with or allergy to anticoagulation
  • Central venous catheters

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01273870


Sponsors and Collaborators
Praxisverbund Dialyse und Apherese
Investigators
Study Director: Roland E Winkler, PhD Praxisverbund fuer Dialyse und Apherese Rostock

Responsible Party: Dr. Peter Ahrenholz, BioArtProducts GmbH, Rostock, Germany
ClinicalTrials.gov Identifier: NCT01273870     History of Changes
Other Study ID Numbers: PDA-02
First Posted: January 11, 2011    Key Record Dates
Last Update Posted: February 2, 2011
Last Verified: November 2010

Keywords provided by Praxisverbund Dialyse und Apherese:
hemodialysis
high-flux-dialyzer
performance
blood compatibility

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Failure, Chronic
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic